Analytical Data
-
Gene name
FGFR-4
-
简介
The leptin R/LEPR protein is a receptor protein that binds to the hormone leptin. It plays a vital role in regulating energy balance and body weight. FGFR-4 Protein, Human (HEK293, Fc) is the recombinant human-derived FGFR-4 protein, expressed by HEK293 , with C-hFc labeled tag.
- Application
-
Biological Activity
1. Measured by its ability to inhibit FGF acidic (aFGF / FGF1) dependent proliferation of Balb/c3T3 mouse embryonic fibroblasts and the ED50 is typically 4-25 ng/mL. 2. Measured by its ability to inhibit FGF acidic-dependent proliferation of NIH-3T3 mouse fibroblast cells. The ED50 of this effect is 2.694 ng/mL in the presence of 1ng/mL FGF-1, corresponding to a specific activity is 3.71×105 units/mg. Measured by its ability to inhibit FGF acidic-dependent proliferation of NIH-3T3 mouse fibroblast cells. The ED50 of this effect is 2.694 ng/ml in the presence of 1ng/mL FGF-1, corresponding to a specific activity is 3.71×105 units/mg.
-
Alternative Names
Fibroblast growth factor receptor 4; FGFR-4; CD334; JTK2; TKF
-
Species
Human
-
Source
HEK293
-
Tag
C-hFc
-
Purity
Greater than 95% as determined by reducing SDS-PAGE.
-
Uniprot
NP_002002.3
-
Expression Region
L22-D369
-
AA Sequence
LEASEEVELEPCLAPSLEQQEQELTVALGQPVRLCCGRAERGGHWYKEGSRLAPAGRVRGWRGRLEIASFLPEDAGRYLCLARGSMIVLQNLTLITGDSLTSSNDDEDPKSHRDPSNRHSYPQQAPYWTHPQRMEKKLHAVPAGNTVKFRCPAAGNPTPTIRWLKDGQAFHGENRIGGIRLRHQHWSLVMESVVPSDRGTYTCLVENAVGSIRYNYLLDVLERSPHRPILQAGLPANTTAVVGSDVELLCKVYSDAQPHIQWLKHIVINGSSFGADGFPYVQVLKTADINSSEVEVLYLRNVSAEDAGEYTCLAGNSIGLSYQSAWLTVLPEEDPTWTAAAPEARYTD
-
Protein Length
Partial
-
Molecular Weight
95-112 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Related Products
Protein Description
Fibroblast Growth Factor Receptor 4 (FGFR4) is a member of the fibroblast growth factor receptor family, which plays a crucial role in various biological processes, including cell growth, differentiation, and metabolism. FGFR4 is particularly associated with the progression of several types of cancers, such as hepatocellular carcinoma and prostate cancer, where its overexpression correlates with poor prognosis. Given its significant role in tumorigenesis, FGFR4 has emerged as a potential therapeutic target, driving research into the development of FGFR4-specific inhibitors and therapies. The study of FGFR4 recombinant proteins is vital for understanding its structure-function relationships and interactions with ligands, which can inform the design of selective inhibitors. Furthermore, recombinant FGFR4 proteins facilitate the investigation of downstream signaling pathways, such as the MAPK and PI3K/Akt pathways, that are activated upon FGFR4 engagement. Advances in biotechnological methods have enabled the production of these proteins in various systems, allowing researchers to conduct detailed functional assays and structural analyses. Overall, the characterization of FGFR4 recombinant proteins is a foundational step in developing targeted therapeutics aimed at treating FGFR4-driven malignancies and improving clinical outcomes for patients.
